transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2020-12-1-42-48transplantologiya-478Research ArticleОБЗОРНЫЕ СТАТЬИ И ЛЕКЦИИREVIEW ARTICLES AND LECTURESК вопросу о трансплантации донорского сердца с гипертрофией миокарда левого желудочкаRevisiting the transplantation of donor heart with left ventricular myocardial hypertrophyhttps://orcid.org/0000-0002-0316-8410ПоповМ. А.PopovM. A.

Михаил Александрович Попов, научный сотрудник отделения кардиохирургии, врач сердечно-сосудистый хирург 

Mikhail A. Popov Research Associate of the Cardiac Surgery Department, Cardiovascular Surgeon

popovcardio88@mail.ruhttps://orcid.org/0000-0003-4204-8865ШумаковД. В.ShumakovD. V.

Дмитрий Валерьевич Шумаков чл.-корр. РАН, проф., руководитель отдела хирургии сердца и сосудов

Dmitriy V. Shumakov Corr. Member of RAS, Prof., Head of the Department of Surgery of Heart and Vessels

https://orcid.org/0000-0001-7087-5441ЗыбинД. И.ZybinD. I.

Дмитрий Игоревич Зыбин канд. мед. наук, заведующий отделением кардиохирургии

Dmitriy I. Zybin Cand. Med. Sci., Head of the Cardiac Surgery Department

https://orcid.org/0000-0002-6074-1201АгафоновЕ. Г.AgafonovE. G.

Евгений Геннадьевич Агафонов научный сотрудник отделения кардиохирургии, врач сердечно-сосудистый хирург

Evgeniy G. Agafonov Research Associate of the Cardiac Surgery Department, Cardiovascular Surgeon

ГБУЗ МО МОНИКИ им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical Institute n.a. M.F. VladimirskiyRussian Federation2020180320201214248Copyright © Попов М.А., Шумаков Д.В., Зыбин Д.И., Агафонов Е.Г., 20202020Попов М.А., Шумаков Д.В., Зыбин Д.И., Агафонов Е.Г.Popov M.A., Shumakov D.V., Zybin D.I., Agafonov E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/478

Несмотря на широкое использование механических систем поддержки кровообращения, современной оптимальной медикаментозной терапии и различных интервенционных методов, трансплантация сердца остается «золотым стандартом» в лечении пациентов с терминальной формой сердечной недостаточности. В то же время необходимый объем трансплантаций сердца в значительной степени ограничен прогрессивно увеличивающейся потребностью в донорских органах и реальным донорским пулом. За последние годы отмечается тенденция к увеличению количества реципиентов и снижению количества донорских органов. Вместе с тем, использование донорских сердец с патологическими изменениями, в том числе гипертрофией миокарда левого желудочка, по-прежнему остается дискутабельной темой. Считается, что использование расширенных критериев существенно повышает риск недостаточности трансплантата в посттрансплантационном периоде и приводит к ухудшению ближайших и отдаленных результатов. Настоящая работа посвящена анализу данных по использованию аллотрансплантатов сердца с гипертрофией миокарда для трансплантации.

Авторы заявляют об отсутствии конфликта интересов.

Despite the widespread use of mechanical circulatory support systems, modern optimal drug therapy and various interventional methods of heart transplantation remain the "gold standard" for the treatment of end-stage heart failure patients.

At the same time the required number of heart transplants is significantly increasing due to the progressively increasing number of patients needing transplants and the actual donor pool. In recent years there has been a trend towards the increase in the number of recipients and the decrease in the number of donor organs. However, the use of donor hearts with pathological changes, including left ventricular myocardial hypertrophy, remains a controversial topic. It is believed that the use of expanded criteria significantly increases the risk of graft failure in the post-transplant period and leads to deterioration of immediate and long-term results. This work aimed to analyze the data on using donor hearts with left ventricular myocardial hypertrophy for allotransplantation.

Authors declare no conflict of interest.

трансплантация сердцагипертрофия миокарда левого желудочкаорганы с расширенными критериями использованиядоноры с расширенными критериямитерминальная сердечная недостаточностьheart transplantationleft ventricular myocardial hypertrophyexpanded criteria organsexpanded criteria donorterminal heart failureИсследование проводилось без спонсорской поддержки.The study was performed without external funding.ReferencesMesserley FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591–603. PMID: 17707755 https://doi.org/10.1016/s0140-6736(07)61299-9Messerley FH, Williams B, Ritz E. Essential hypertension. Lancet. 2007;370(9587):591–603. PMID: 17707755 https://doi.org/10.1016/s0140-6736(07)61299-9Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, et al. Left ventricular hypertrophy, subclinical atherosclerosis and inflammation. Hypertension. 2007;49(6):1385– 1391. PMID: 17404181 https://doi.org/10.1161/hypertensionaha.107.087890Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, et al. Left ventricular hypertrophy, subclinical atherosclerosis and inflammation. Hypertension. 2007;49(6):1385– 1391. PMID: 17404181 https://doi.org/10.1161/hypertensionaha.107.087890Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli VP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566. PMID: 2139921 https://doi.org/10.1056/nejm199005313222203Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli VP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–1566. PMID: 2139921 https://doi.org/10.1056/nejm199005313222203Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345–352. PMID: 1825164 https://doi.org/10.7326/0003-4819-114- 5-345Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345–352. PMID: 1825164 https://doi.org/10.7326/0003-4819-114- 5-345Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendation for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108. PMID: 16458610 https://doi.org/10.1016/j.euje.2005.12.014Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendation for chamber quantification. Eur J Echocardiogr. 2006;7(2):79–108. PMID: 16458610 https://doi.org/10.1016/j.euje.2005.12.014Russo MJ, Davies RR, Hong KN, Chen JM, Argenziano M, Moskowitz A, et al. Matching high-risk recipients with marginal donor hearts is a clinically effective strategy. Ann Thorac Surg. 2009;87(4):1066–1070. PMID: 19324129 https://doi.org/10.1016/j. athoracsur.2008.12.020Russo MJ, Davies RR, Hong KN, Chen JM, Argenziano M, Moskowitz A, et al. Matching high-risk recipients with marginal donor hearts is a clinically effective strategy. Ann Thorac Surg. 2009;87(4):1066–1070. PMID: 19324129 https://doi.org/10.1016/j. athoracsur.2008.12.020Wever PO, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant. 2011;11(12):2755– 2761. PMID: 21906259 https://doi.org/10.1111/j.1600-6143.2011.03744.xWever PO, Stoddard G, Drakos SG, Gilbert EM, Nativi JN, Budge D, et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant. 2011;11(12):2755– 2761. PMID: 21906259 https://doi.org/10.1111/j.1600-6143.2011.03744.xKhush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail. 2013;6(2):300–309. PMID: 23392789 https://doi.org/10.1161/circheartfailure.112.000165Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail. 2013;6(2):300–309. PMID: 23392789 https://doi.org/10.1161/circheartfailure.112.000165Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: implications regarding use of dysfunctional hearts for successful transplantation. J Am Coll Cardiol. 2012;60(3):235– 236. PMID: 22789890 https://doi.org/10.1016/j.jacc.2012.04.016Mohamedali B, Bhat G, Zelinger A. Frequency and pattern of left ventricular dysfunction in potential heart donors: implications regarding use of dysfunctional hearts for successful transplantation. J Am Coll Cardiol. 2012;60(3):235– 236. PMID: 22789890 https://doi.org/10.1016/j.jacc.2012.04.016Venkateswaran RV, Townend JN, Wilson IC, Mascaro JG, Bonser RS, Steeds RP. Echocardiography in the potential heart donor. Transplantation. 2010;89(7):894–901. PMID: 20075789 https://doi.org/10.1097/tp.0b013e3181cfe8e9Venkateswaran RV, Townend JN, Wilson IC, Mascaro JG, Bonser RS, Steeds RP. Echocardiography in the potential heart donor. Transplantation. 2010;89(7):894–901. PMID: 20075789 https://doi.org/10.1097/tp.0b013e3181cfe8e9Zaroff JG, Babcock WD, Shi boski SC, Solinger LL, Rosengard BR. Temporal changes in left ventricular systolic function in heart donors: results of serial echocardiography. J Heart Lung Transplant. 2003;22(4):383–388. PMID: 12681416 https://doi.org/10.1016/s1053-2498(02)00561-2Zaroff JG, Babcock WD, Shi boski SC, Solinger LL, Rosengard BR. Temporal changes in left ventricular systolic function in heart donors: results of serial echocardiography. J Heart Lung Transplant. 2003;22(4):383–388. PMID: 12681416 https://doi.org/10.1016/s1053-2498(02)00561-2Chen CW, Sprys MH, Gaffey AC, Chung JJ, Margulies KB, Acker MA, et al. The low ejection fraction in donor hearts is not directly related to increase recipient mortality. J Heart Lung Transplant. 2017;36(6):611– 615. PMID: 28314504 https://doi.org/10.1016/j.healun.2017.02.001Chen CW, Sprys MH, Gaffey AC, Chung JJ, Margulies KB, Acker MA, et al. The low ejection fraction in donor hearts is not directly related to increase recipient mortality. J Heart Lung Transplant. 2017;36(6):611– 615. PMID: 28314504 https://doi.org/10.1016/j.healun.2017.02.001Marelli D, Laks H, Fazio D, Moore S, Moriguchi J,Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant. 2000;19(5):496–503. PMID: 10808159 https://doi.org/10.1016/s1053-2498(00)00076-0Marelli D, Laks H, Fazio D, Moore S, Moriguchi J,Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant. 2000;19(5):496–503. PMID: 10808159 https://doi.org/10.1016/s1053-2498(00)00076-0Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC, Wehe KM, et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int. 1997;10(6):446–450. PMID: 9428118 https://doi.org/10.1007/s001470050084Aziz S, Soine LA, Lewis SL, Kruse AP, Levy WC, Wehe KM, et al. Donor left ventricular hypertrophy increases risk for early graft failure. Transpl Int. 1997;10(6):446–450. PMID: 9428118 https://doi.org/10.1007/s001470050084Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008;51(12):1214– 1220. PMID: 18355661 https://doi.org/10.1016/j.jacc.2007.11.052Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol. 2008;51(12):1214– 1220. PMID: 18355661 https://doi.org/10.1016/j.jacc.2007.11.052Kittleson M, Patel J, Chang DH, Kransdorf E, Levine R, Dimbil S, et al. Donor left ventricular hypertrophy: over-rated or does donor history of hypertension make a difference for post-heart transplant outcome? J Heart Lung Transplantation. 2019;38(4 Suppl):S269. https://doi.org/10.1016/j. healun.2019.01.670Kittleson M, Patel J, Chang DH, Kransdorf E, Levine R, Dimbil S, et al. Donor left ventricular hypertrophy: over-rated or does donor history of hypertension make a difference for post-heart transplant outcome? J Heart Lung Transplantation. 2019;38(4 Suppl):S269. https://doi.org/10.1016/j. healun.2019.01.670Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbacher DG, et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-. Circulation. 2001;104(6):676–681. https://doi.org/10.1161/hc3101.093765Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbacher DG, et al. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-. Circulation. 2001;104(6):676–681. https://doi.org/10.1161/hc3101.093765Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor- provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–1252. PMID: 9054856 https://doi.org/10.1161/01.cir.95.5.1247Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor- provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–1252. PMID: 9054856 https://doi.org/10.1161/01.cir.95.5.1247McKoy RC, Uretsky BF, Kormos R, Hardesty RL, Griffith BP, Salerni R, et al. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol. 1988;62(4):1140– 1142. PMID: 2973223 https://doi.org/10.1016/0002-9149(88)90570-xMcKoy RC, Uretsky BF, Kormos R, Hardesty RL, Griffith BP, Salerni R, et al. Left ventricular hypertrophy in cyclosporine-induced systemic hypertension after cardiac transplantation. Am J Cardiol. 1988;62(4):1140– 1142. PMID: 2973223 https://doi.org/10.1016/0002-9149(88)90570-xVentura HO, Lavie CJ, Messerli FH, Valentino V, Smart FW, Stapleton DD, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens. 1994;8(4):233–237. PMID: 8021902Ventura HO, Lavie CJ, Messerli FH, Valentino V, Smart FW, Stapleton DD, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. J Hum Hypertens. 1994;8(4):233–237. PMID: 8021902Calò L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transplant Int. 2000;13(Suppl 1):413–418. PMID: 11112045 https://doi.org/10.1007/s001470050374Calò L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transplant Int. 2000;13(Suppl 1):413–418. PMID: 11112045 https://doi.org/10.1007/s001470050374Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporine-Induced Hypertension: incidence, pathogenesis and management. Drug Safety. 1999;20(5):437–449. PMID: 10348094 https://doi.org/10.2165/00002018- 199920050-00004Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporine-Induced Hypertension: incidence, pathogenesis and management. Drug Safety. 1999;20(5):437–449. PMID: 10348094 https://doi.org/10.2165/00002018- 199920050-00004Goodroe R, Bonnema DD, Lunsford S, Anderson P, Ryan-Baille B, Uber W, et al. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007;26(2):145– 151. PMID: 17258148 https://doi.org/10.1016/j.healun.2006.11.003Goodroe R, Bonnema DD, Lunsford S, Anderson P, Ryan-Baille B, Uber W, et al. Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients. J Heart Lung Transplant. 2007;26(2):145– 151. PMID: 17258148 https://doi.org/10.1016/j.healun.2006.11.003Morgan JA, John R, Weinberg AD, Remoli R, Kherani AR, Vigilance DW, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg. 2003;76(6):1982–1987. PMID: 14667625 https://doi.org/10.1016/s0003-4975(03)01070-1Morgan JA, John R, Weinberg AD, Remoli R, Kherani AR, Vigilance DW, et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg. 2003;76(6):1982–1987. PMID: 14667625 https://doi.org/10.1016/s0003-4975(03)01070-1Everett JE, Djalilian AR, Kubo SH, Kroshus TJ, Shumway SJ. Heart transplantation for patients over age 60. Clin Transplant. 1996;10(6Pt1):478–81. PMID: 8996766Everett JE, Djalilian AR, Kubo SH, Kroshus TJ, Shumway SJ. Heart transplantation for patients over age 60. Clin Transplant. 1996;10(6Pt1):478–81. PMID: 8996766Blanche C, Blanche DA, Kearney B, Sandhu M, Czer LS, Kamlot A, et al. Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome. J Thorac Cardiovasc Surg. 2001;121(3):532–541. PMID: 11241089 https://doi.org/10.1067/mtc.2001.112831Blanche C, Blanche DA, Kearney B, Sandhu M, Czer LS, Kamlot A, et al. Heart transplantation in patients seventy years of age and older: A comparative analysis of outcome. J Thorac Cardiovasc Surg. 2001;121(3):532–541. PMID: 11241089 https://doi.org/10.1067/mtc.2001.112831Marelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2(5):443– 447. PMID: 12123210 https://doi.org/10.1034/j.1600-6143.2002.20508.xMarelli D, Bresson J, Laks H, Kubak B, Fonarow G, Tsai FC, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant. 2002;2(5):443– 447. PMID: 12123210 https://doi.org/10.1034/j.1600-6143.2002.20508.xLaks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg. 2003;125(1):49–59. PMID: 12538985 https://doi.org/10.1067/mtc.2003.62Laks H, Marelli D, Fonarow GC, Hamilton MA, Ardehali A, Moriguchi JD, et al. Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg. 2003;125(1):49–59. PMID: 12538985 https://doi.org/10.1067/mtc.2003.62Laks H, Marelli D. The alternate recipient list for heart transplantation: a model for expansion of the donor pool. Adv Card Surg. 1999;11:233–244. PMID: 10575495Laks H, Marelli D. The alternate recipient list for heart transplantation: a model for expansion of the donor pool. Adv Card Surg. 1999;11:233–244. PMID: 10575495Шевченко А.О., Фараджов Р.А., Изотов Д.А., Колоскова Н.Н., Никитина Е.А., Гичкун О.Е. и др. Ингибиторы ангиотензинпревращающего фермента у реципиентов сердца: результаты одноцентрового исследования. Вестник трансплантологии и искусственных органов. 2018;20(4):14–21.Shevchenko АО, Faradzhov RA, Izotov DA, Koloskova NN, Nikitina ЕA, Gichkun OE, et al. The effects of angiotensin-converting enzyme inhibitors in heart recipients: a single center experience. Russian Journal of Transplantology and Artificial Organs. 2018;20(4):14–21. (In Russ.). https://doi.org/10.15825/1995-1191-2018-4-14-21Попцов В.Н., СпиринаЕ.А., Устин С.Ю., Масютин С.А., Догонашева А.А., Воронков В.Ю. и др. Трансплантация донорского сердца с гипертрофией миокарда левого желудочка 1,5 см и более. Вестник трансплантологии и искусственных органов. 2019;21(1):7–16.Poptsov VN, Spirina EA, Ustin SYu, Masutin SA, Dogonacheva AA, Voronkov VYu, et al. Transplantation of cardiac allografts with left ventricular hypertrophy 1.5 cm and more. Russian Journal of Transplantology and Artificial Organs. 2019;21(1):7–16. (In Russ.). https://doi.org/10.15825/1995-1191-2019-1-7-16

The authors declare that there are no conflicts of interest present.